Pharmacokinetics and bioavailability of palonosetron hydrochloride capsules in healthy volunteers

SHI Xiang-ling,SHAO Fang-xian,SONG Min,HANG Tai-jun,YANG Lin,WEN Ai-dong,ZHANG Xi-quan,DAI Jun,WANG Yan-xia,Kun Li

2013-01-01

Abstract:Objective:To characterize the pharmacokinetics and bioavailability of palonosetron hydrochloride capsules in healthy Chinese volunteers.Methods:In this randomized,crossover and self-control study,twelve healthy volunteers with equal gender were administered with single oral dose of 0.25 or 0.75 mg palonosetron;another group of twelve healthy volunteers were administered with single oral dose or intravenous injection of 0.5 mg palonosetron.Blood samples were collected in predetermined time intervals up to 168 h.The plasma concentration of palonosetron was determined by a validated LC-MS/MS method.The pharmacokinetic parameters were estimated by DAS2.1 software.Results:The pharmacokinetic parameters of palonosetron after a single oral dose of 0.25 and 0.75 mg were as follows:Cmax(0.58±0.20) and(1.95±0.94) ng·mL-1,Tmax(8.4±3.9) and(8.3±2.9) h,AUC0~168(35±10) and(82±34) h·ng·mL-1,and t1/2(74±18) and(41±9) h,respectively.The Cmax after a single oral and intravenous dose of 0.5 mg were(0.82±0.17) and(5.58±2.66) ng·mL-1,Tmax(6.3 4.3) and(0.022±0.019) h,AUC0~168(43±12) and(40±12) h·ng·mL-1,t1/2(44±9) and(54±18) h,respectively.The absolute bioavailability of palonosetron hydrochloride capsules was estimated to be(109.9±26.1)%.Conclusion:Linear pharmacokinetics was found for palonosetron after single oral dose in the range of 0.25 and 0.75 mg in healthy Chinese volunteers.After oral administration,the Tmax was delayed and the Cmax values were much lower compared with the intravenous injection.No significant differences were found for the pharmacokinetic parameters between male and female volunteers(P>0.05).